DDInter825 DDInter1055
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) downregulates {v} (Gene) TES
TES {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Glimepiride {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glimepiride may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Levofloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) downregulates TES (Gene) and TES (Gene) is downregulated by Levofloxacin (Compound)
Glimepiride (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)